argenx NV ADR (ARGX)vsCan Fite Biopharma Ltd ADR (CANF)
ARGX
argenx NV ADR
$882.56
+1.18%
HEALTHCARE · Cap: $54.24B
CANF
Can Fite Biopharma Ltd ADR
$3.20
+1.27%
HEALTHCARE · Cap: $6.92M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 1312361% more annual revenue ($5.32B vs $405,000). ARGX leads profitability with a 32.3% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
CANF
Avoid20
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+65.6%
Fair Value
$2427.69
Current Price
$882.56
$1545.13 discount
Margin of Safety
+59.6%
Fair Value
$10.89
Current Price
$3.20
$7.69 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 186.6x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bull Case : CANF
The strongest argument for CANF centers on Price/Book, Debt/Equity.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : CANF
The primary concerns for CANF are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ARGX profiles as a growth stock while CANF is a value play — different risk/reward profiles.
CANF carries more volatility with a beta of 0.02 — expect wider price swings.
ARGX is growing revenue faster at 59.3% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 20/100), backed by strong 32.3% margins and 59.3% revenue growth. CANF offers better value entry with a 59.6% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Can Fite Biopharma Ltd ADR
HEALTHCARE · BIOTECHNOLOGY · USA
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutics for the treatment of cancer, liver and inflammatory diseases, COVID-19, and erectile dysfunction. The company is headquartered in Petah-Tikva, Israel.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?